These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27910036)

  • 1. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.
    Salem AH; Hu B; Freise KJ; Agarwal SK; Sidhu DS; Wong SL
    Clin Drug Investig; 2017 Mar; 37(3):303-309. PubMed ID: 27910036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
    Yin OQ; Gallagher N; Fischer D; Zhao L; Zhou W; Leroy E; Golor G; Schran H
    Clin Drug Investig; 2011; 31(3):169-79. PubMed ID: 21184622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin.
    Chiney MS; Menon RM; Bueno OF; Tong B; Salem AH
    Xenobiotica; 2018 Sep; 48(9):904-910. PubMed ID: 29027832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral vitamin K on S- and R-warfarin pharmacokinetics and pharmacodynamics: enhanced safety of warfarin as a CYP2C9 probe.
    Kim JS; Nafziger AN; Gaedigk A; Dickmann LJ; Rettie AE; Bertino JS
    J Clin Pharmacol; 2001 Jul; 41(7):715-22. PubMed ID: 11452703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Malhotra B; Alvey C; Gong J; Li X; Duczynski G; Gandelman K
    Br J Clin Pharmacol; 2011 Aug; 72(2):257-62. PubMed ID: 21496065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of linagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Graefe-Mody EU; Brand T; Ring A; Withopf B; Stangier J; Iovino M; Woerle HJ
    Int J Clin Pharmacol Ther; 2011 May; 49(5):300-10. PubMed ID: 21543033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
    Freise KJ; Hu B; Salem AH
    Eur J Clin Pharmacol; 2018 Apr; 74(4):413-421. PubMed ID: 29302721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
    Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
    Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H; Patat A; Parks V; Buckwalter M; Metzger D; Korth-Bradley J
    J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parameters.
    Braeckman RA; Stirtan WG; Soni PN
    Clin Drug Investig; 2014 Jul; 34(7):449-56. PubMed ID: 24760401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
    Agarwal SK; Hu B; Chien D; Wong SL; Salem AH
    J Clin Pharmacol; 2016 Nov; 56(11):1335-1343. PubMed ID: 26953185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
    Simonson SG; Martin PD; Mitchell PD; Lasseter K; Gibson G; Schneck DW
    J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
    Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
    Agarwal SK; Tong B; Bueno OF; Menon RM; Salem AH
    Adv Ther; 2018 Nov; 35(11):2015-2023. PubMed ID: 30264382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of torsemide on pharmacodynamics and pharmacokinetics of warfarin in humans and rats.
    Kim HO; Lee KE; Park HY; Lee NR; Oh BR; Chang BC; Gwak HS
    J Pharm Pharmacol; 2013 Aug; 65(8):1195-203. PubMed ID: 23837587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers.
    Macha S; Rose P; Mattheus M; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Apr; 15(4):316-23. PubMed ID: 23094794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
    Agarwal SK; Salem AH; Danilov AV; Hu B; Puvvada S; Gutierrez M; Chien D; Lewis LD; Wong SL
    Br J Clin Pharmacol; 2017 Apr; 83(4):846-854. PubMed ID: 27859472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Almeida L; Falcão A; Vaz-da-Silva M; Nunes T; Santos AT; Rocha JF; Neta C; Macedo T; Fontes-Ribeiro C; Soares-da-Silva P
    Eur J Clin Pharmacol; 2008 Oct; 64(10):961-6. PubMed ID: 18679669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.